GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (STU:SG0) » Definitions » Other Gross PPE

FibroBiologics (STU:SG0) Other Gross PPE : €2.11 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Other Gross PPE?

FibroBiologics's Other Gross PPE for the quarter that ended in Mar. 2025 was €2.11 Mil.

FibroBiologics's quarterly Other Gross PPE increased from Sep. 2024 (€2.15 Mil) to Dec. 2024 (€2.27 Mil) but then declined from Dec. 2024 (€2.27 Mil) to Mar. 2025 (€2.11 Mil).

FibroBiologics's annual Other Gross PPE increased from Dec. 2022 (€2.08 Mil) to Dec. 2023 (€2.41 Mil) but then declined from Dec. 2023 (€2.41 Mil) to Dec. 2024 (€2.27 Mil).


FibroBiologics Other Gross PPE Historical Data

The historical data trend for FibroBiologics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Other Gross PPE Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Other Gross PPE
- 2.08 2.41 2.27

FibroBiologics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.32 2.30 2.15 2.27 2.11

FibroBiologics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


FibroBiologics Business Description

Traded in Other Exchanges
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

FibroBiologics Headlines

No Headlines